ATYR at a glance
aTYR PHARMA INC (ATYR, SEC CIK 1339970) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), aTYR PHARMA INC (ATYR) reported revenue of $190,000 (down 19.1% from FY2024) and a net loss of $74.1 million. Diluted EPS was -$0.80.
- As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding aTYR PHARMA INC (ATYR) shares worth $2.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by SCHIMMEL PAUL on May 27, 2026 of 100,000 shares at $0.50 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $190K
- −19.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $2.9M · −3 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added regulatory risk: FDA viewed EFZO-FIT as failed, with the Proposed Phase 3 Study potentially insufficient for approval
- Most material operational change: CDMO received a March 2026 Form 483 and plans microbial-site relocation, threatening future manufacturing continuity
- Most impactful financial risk: $50.3 million available liquidity, with additional capital needed for later clinical development and commercialization
- Near-term execution risk: Proposed Phase 3 Study activities expected in fourth quarter 2026, but advancement depends on securing a strategic partner
- Workforce risk: August 2026 restructuring reduced total employees by approximately 60% to 20 full-time employees
Management Discussion & Analysis
- Revenue $0, down $190,000 YoY from license and collaboration agreement revenue
- R&D expenses $10.4M vs $22.1M YoY, down $11.7M
- Worst performer: efzofitimod expenses $1.5M vs $18.8M, down $17.2M
- Cash, equivalents, restricted cash and investments $50.3M; operating cash used $31.4M
- Near-term outlook: lower expenses after restructuring and strategic-partnership prioritization, with capital needs remaining beyond one year
AI summary of the ATYR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Nasdaq minimum bid-price compliance restored after shares closed at least $1.00 for 10 consecutive business days
- Compliance period ran October 30 through November 12, 2026
Item 8.01: Other Events
- ATM equity offering of up to $79,994,251 through Jefferies under the existing Sales Agreement
- Potential share issuance creates dilution risk for existing ATYR shareholders
Item 2.02: Results of Operations and Financial Condition
- Press release covers aTyr Pharma’s quarter ended September 30, 2026
- Financial results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FDA-aligned Phase 3 efzofitimod protocol, using FVC as primary endpoint, moves pulmonary sarcoidosis program toward pivotal testing
- Strategic partnerships or licensing now prioritized, creating execution and funding dependence on external financing or collaboration
AI summaries of ATYR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ATYR
Don't miss the next ATYR filing
- Alerts as it files. A push when ATYR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ATYR, by share count.
- Ask anything. An AI agent that reads every ATYR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Yaras Brandon | A | Oct 1, 2026 | 410,000 | - |
| SCHIMMEL PAUL | Buy | May 27, 2026 | 100,000 | $0.50 |
| Zaknoen Sara | A | May 11, 2026 | 50,000 | - |
| Gross Jane A | A | May 11, 2026 | 50,000 | - |
| BENEVICH ERIC | A | May 11, 2026 | 50,000 | - |
| SCHIMMEL PAUL | A | May 11, 2026 | 50,000 | - |
| Gross Jane A | A | May 11, 2026 | 50,000 | - |
| Coughlin Timothy | A | May 11, 2026 | 50,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $353K | $235K | $190K |
| Operating Income | - | -$67.9M | -$77.6M |
| Net Income | -$50.4M | -$64.0M | -$74.1M |
| Op. Margin | - | -28899.6% | -40856.3% |
| Net Margin | -14274.5% | -27243.8% | -39009.5% |
| Balance Sheet | |||
| Total Assets | - | $96.8M | $93.0M |
| Equity | $90.7M | $70.0M | $67.5M |
| ROE | -55.6% | -91.4% | -109.8% |
| Per Share | |||
| EPS | $-0.94 | $-0.86 | $-0.80 |
| Cash Flow | |||
| Operating CF | - | -$69.1M | -$62.0M |
| CapEx | - | $65K | $77K |
Source: XBRL data in aTYR PHARMA INC (ATYR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ATYR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 16 | $2.9M |
| Q2 2026 | 19 | $10.3M |
| Q1 2026 | 24 | $26.3M |
| Q4 2025 | 20 | $25.6M |
| Q3 2025 | 23 | $26.8M |
| Q2 2025 | 22 | $152.9M |
| Q1 2025 | 14 | $64.3M |
| Q4 2024 | 11 | $63.6M |
- Renaissance Technologies LLC+116.3K (+70%)
- Bank of America Corp+16.2K (+8%)
- AQR Capital Management−1.92M (-74%)
- Two Sigma Investments−1.01M (-81%)
- Goldman Sachs Group−463.9K (-72%)
- Morgan Stanley−242.9K (-18%)
- BlackRock−206.8K (-11%)
- StoneX Group Inc.+105.0K
- FMR LLC (Fidelity)−2.47M
- Citadel Advisors LLC−1.24M
- Dimensional Fund Advisors−90.9K
- PNC Financial Services−1.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 149 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ATYR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 15, 2026 | - | Analysis | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 5, 2026 | - | - | - |
| 4 | Feb 4, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
ATYR SEC filings: frequently asked questions
Which institutions hold ATYR stock?
As of September 30, 2026, the largest aTYR PHARMA INC (ATYR) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.1 million), BlackRock ($491,000), Morgan Stanley ($334,000), AQR Capital Management ($209,000), Millennium Management ($176,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ATYR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), aTYR PHARMA INC (ATYR) reported revenue of $190,000 (down 19.1% from FY2024) and a net loss of $74.1 million. Diluted EPS was -$0.80. The figures come from the XBRL data in the 10-K.
What did ATYR report in its latest 8-K?
aTYR PHARMA INC (ATYR) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). Nasdaq minimum bid-price compliance restored after shares closed at least $1.00 for 10 consecutive business days.
What are the latest ATYR SEC filings?
aTYR PHARMA INC (ATYR) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on October 1, 2026.
What is ATYR's SEC CIK number?
aTYR PHARMA INC (ATYR)'s SEC Central Index Key (CIK) is 1339970. EDGAR lists every ATYR filing under that number.
Ask anything about ATYR
The research agent reads ATYR's filings, financials, insider trades and 13F holders, then answers with sources.